Morepen Bio Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 8.87 Cr
- Company Age 24 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 1587.50%
- Ebitda 1770.83%
- Net Worth 29.68%
- Total Assets 360.00%
About Morepen Bio
Morepen Bio Limited (MBL) is a Public Limited Indian Non-Government Company incorporated in India on 10 July 2000 and has a history of 24 years and seven months. Its registered office is in Himachal Pradesh, Himachal Pradesh.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 8.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Suri, Anju Suri, and Shalu Suri serve as directors at the Company.
Company Details
- Location Himachal Pradesh, Himachal Pradesh
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232HP2000PLC023823
- Company No.
023823
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 Jul 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Who are the key members and board of directors at Morepen Bio?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shalu Suri  | Director | 26-Aug-2003 | Current |
| Sanjay Suri | Director | 01-Dec-2022 | Current |
| Anju Suri | Director | 26-Aug-2003 | Current |
Financial Performance of Morepen Bio.
Morepen Bio Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 1587.5% increase in profit. The company's net worth Soared by an impressive increase of 29.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Morepen Bio?
In 2023, Morepen Bio had a promoter holding of 56.40% and a public holding of 43.60%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Blue Coast Hospitality LimitedShalu Suri is a mutual person
Morepen Laboratories LimitedSanjay Suri is a mutual person
- Morepen Rx Limited
Sanjay Suri and Shalu Suri are mutual person
- Morepen Devices Limited
Shalu Suri is a mutual person
Morepen Proprietary Drug Research Private LimitedSanjay Suri and Shalu Suri are mutual person
- Total Care Limited
Sanjay Suri is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Morepen Bio?
Unlock and access historical data on people associated with Morepen Bio, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Morepen Bio, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Morepen Bio's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
